Anonymous User
Login / Registration

a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2019; 73(6): 501–508. doi:10.14735/amgh2019501.

Focal inflammatory liver lesions

Vladimír Frýba1, Jan Ulrych1, Hana Kristianová1, Zdeněk Krška1

+ Affiliation


Focal inflammatory liver lesions are a heterogeneous group of diseases that involve both infectious and non-infectious inflammatory processes. The most frequent type of infectious inflammatory hepatic lesions are abscesses of different origins (pyogenic, amoebic, fungal), followed by parasitic liver cysts and, rarely, by tuberculosis of the liver. Non-infectious inflammatory processes include sarcoidosis of the liver and hepatic inflammatory pseudotumors. This article reviews the etiopathogenesis, clinical manifestations, diagnosis, and therapy of particular focal hepatic inflammatory processes.


liver abscess, amoebic abscess, echinoccocosis, focal liver lesion, inflammation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users


1. Rahimian J, Wilson T, Oram V et al. Pyogenic liver abscess: recent trends in etiology and mortality. Clin Infect Dis 2004; 39 (11): 1654–1659. doi: 10.1086/425616.
2. Meddings L, Myers RP, Hubbard J et al. A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends. Am J Gastroenterol 2010; 105 (1): 117–124. doi: 10.1038/ajg.2009.614.
3. Yoon JH, Kim YJ, Kim SI. Prognosis of liver abscess with no identified organism. BMC Infect Dis 2019; 19 (1): 488. doi: 10.1186/s128 79-019-4131-z.
4. Kaplan GG, Gregson DB, Laupland KB. Population-based study of the epidemiology of and the risk factors for pyogenic liver abscess. Clin Gastroenterol Hepatol 2004; 2 (11): 1032–1038. doi: 10.1016/s1542-3565 (04) 00459-8.
5. Longworth S, Han J. Pyogenic liver abscess. Clin Liver Dis (Hoboken) 2015; 6 (2): 51–54. doi: 10.1002/cld.487.
6. Barosa R, Pinto J, Caldeira A et al. Modern role of clinical ultrasound in liver abscess and echinococcosis. J Med Ultrason (2001) 2017; 44 (3): 239–245. doi: 10.1007/s10396-016-0765-2.
7. Tsai FC, Huang YT, Chang LY et al. Pyogenic liver abscess as endemic disease, Taiwan. Emerg Infect Dis 2008; 14 (10): 1592–1600. doi: 10.3201/eid1410.071254.
8. Moore R, O’Shea D, Geoghegan T et al. Community-acquired Klebsiella pneumoniae liver abscess: an emerging infection in Ireland and Europe. Infection 2013; 41 (3): 681–686. doi: 10.1007/s15010-013-0408-0.
9. Fazili T, Sharngoe C, Endy T et al. Klebsiella pneumoniae liver abscess: an emerging disease. Am J Med Sci 2016; 351 (3): 297–304. doi: 10.1016/j.amjms.2015.12.018.
10. Luo M, Yang XX, Tan B et al. Distribution of common pathogens in patients with pyogenic liver abscess in China: a meta-analysis. Eur J Clin Microbiol Infect Dis 2016; 35 (10): 1557–1565. doi: 10.1007/s10096-016-2712-y.
11. Chemaly RF, Hall GS, Keys TF et al. Microbiol-ogy of liver abscesses and the predictive value of abscess gram stain and associated blood cultures. Diagn Microbiol Infect Dis 2003; 46 (4): 245–248. doi: 10.1016/s0732-8893 (03) 00088-9.
12. Shelat VG, Wang Q, Chia CL et al. Patients with culture negative pyogenic liver abscess have the same outcomes compared to those with Klebsiella pneumoniae pyogenic liver abscess. Hepatobiliary Pancreat Dis Int 2016; 15 (5): 504–511. doi: 10.1016/s1499-3872 (16) 60127-3.
13. Sharma BC, Garg V, Reddy R. Endoscopic management of liver abscess with biliary communication. Dig Dis Sci 2012; 57 (2): 524–527. doi: 10.1007/s10620-011-1872-y.
14. Gürlich R, Adámková V, Ulrych J et al. Základní principy diagnostiky a léčby sekundární peritonitidy – doporučení odborníků s podporou SIS. Rozhl Chir 2014; 93 (6): 322–349.
15. Liu Y, Wang JY, Jiang W. An increasing prominent disease of Klebsiella pneumoniae liver abscess: etiology, diagnosis, and treatment. Gastroenterol Res Pract 2013; 258514. doi: 10.1155/2013/258514.
16. Pais-Costa SR, Araujo SLM, Figueiredo VN. Hepatectomy for pyogenic liver abscess treatment: exception approach? Arq Bras Cir Dig 2018; 31 (3): e1394. doi: 10.1590/0102-672020180001e1394.
17. Thaler M, Pastakia B, Shawker TH et al. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108 (1): 88–100. doi: 10.7326/0003-4819-108-1-88.
18. Hasan S, Fearn R. Fungal liver abscess in an immunocompetent patient who underwent repeated ERCPs and subtotal cholecystectomy. BMJ Case Rep 2018; bcr-2017-222013. doi: 10.1136/bcr-2017-222013.
19. Sallah S. Hepatosplenic candidiasis in patients with acute leukemia: increasingly encountered complication. Anticancer Res 1999; 19 (1B): 757–760.
20. Haque R, Huston CD, Hughes M et al. Amebiasis. N Engl J Med 2003; 348 (16): 1565–1573. doi: 10.1056/NEJMra022710.
21. Skappak C, Akierman S, Belga S et al. Invasive amoebiasis: a review of Entamoeba infections highlighted with case reports. Can J Gastroenterol Hepatol 2014; 28 (7): 355–3559. doi: 10.1155/2014/745130.
22. Sharma M, Briski LE, Khatib R. Hepatic actinomycosis: an overview of salient features and outcome of therapy. Scand J Infect Dis 2002; 34 (5): 386–391. doi: 10.1080/00365540110080304.
23. Yang XX, Lin JM, Xu KJ et al. Hepatic actinomycosis: report of one case and analysis of 32 previously reported cases. World J Gastroenterol 2014; 20 (43): 16372–16376. doi: 10.3748/ wjg.v20.i43.16372.
24. Yang SS, Im YC. Severe abdominopelvic actinomycosis with colon perforation and hepatic involvement mimicking advanced sigmoid colon cancer with hepatic metastasis: a case study. BMC Surg 2018; 18 (1): 51. doi: 10.1186/s12893-018-0386-3.
25. Uehara Y, Takahashi T, Yagoshi M et al. Liver abscess of Actinomyces israelii in a hemodialysis patient: case report and review of the literature. Intern Med 2010; 49 (18): 2017–2020.
26. Nunnari G, Pinzone MR, Gruttadauria S et al. Hepatic echinococcosis: clinical and therapeutic aspects. World J Gastroenterol 2012; 18 (13): 1448–1458. doi: 10.3748/wjg.v18.i13. 1448.
27. Brunetti E, Kern P, Vuitton DA et al. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010; 114 (1): 1–16. doi: 10.1016/ j.actatropica.2009.11.001.
28. Jabbour N, Shirazi, SK, Genyk Y et al. Surgical management of complicated hydatid disease of the liver. Am Surg 2002; 68 (11): 984–988.
29. Kristianova H, Kolarova L, Krska Z et al. Surgical treatment of alveolar echinococcosis: a single centre experience and systematic review of the literature. Rozhl Chir 2019; 98 (4): 167–173.
30. Kolářová L, Matějů J, Honzáková L et al. Humánní alveolární echinokokóza a přehled výskytu tasemnic Echinococcus multilocularis u zvířat v České republice. Epidemiol Mikrobiol Imunul 2017; 66 (4): 163−172.
31. Walls T, Shingadia D. The epidemiology of tuberculosis in Europe. Arch Dis Child 2007; 92 (8): 726–729. doi: 10.1136/adc.2006.102889.
32. Pribula V, Bodnár J, Vrzgula A. Tuberkulóza pečene – kazuistika. Rozhl Chir 2018; 97 (8): 394–398.
33. Kharrasse G, Soufi M, Berekhli H et al. Primary tuberculoma of the liver: a case report and literature review. Pan Afr Med J 2014; 19: 321. doi: 10.11604/pamj.2014.19.321.5107.
34. Ungprasert P, Crowson CS, Simonetto DA et al. Clinical characteristics and outcome of hepatic sarcoidosis: a population-based study 1976–2013. Am J Gastroenterol 2017; 112 (10): 1556–1563. doi: 10.1038/ajg.2017.231.
35. Ibrahim AM, Bhandari B, Soriano PK et al. Hepatic involvement in systemic sarcoidosis. Am J Case Rep 2018; 19: 1212–1215. doi: 10.12659/AJCR.910600.
36. Kennedy PT, Zakaria N, Modawi SB et al. Natural history of hepatic sarcoidosis and its response to treatment. Eur J Gastroenterol Hepatol 2006; 18 (7): 721–726. doi: 10.1097/01.meg.0000223911.85739.38.
37. Pack GT, Baker HW. Total right hepatic lobec-tomy: report of a case. Ann Surg 1953; 138 (2):  253–258. doi: 10.1097/00000658-195308000-00012.
38. Chang SD, Scali EP, Abrahams Z et al. Inflammatory pseudotumor of the liver: a rare case of recurrence following surgical resection. J Radiol Case Rep 2014; 8 (3): 23–30. doi: 10.3941/jrcr.v8i3.1459.
39. Biecker E, Zimmermann A, Dufour JF. Spontaneous regression of an inflammatory pseudotumor of the liver. Z Gastroenterol 2003; 41 (10): 991–994. doi: 10.1055/s-2003-42928.
40. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol 2008; 61 (4): 428–437. doi: 10.1136/jcp.2007.049387.
41. Torzilli G, Inoue K, Midorikawa Y et al. Inflammatory pseudotumors of the liver: prevalence and clinical impact in surgical patients. Hepatogastroenterology 2001; 48 (40): 1118–1123.

Kreditovaný autodidaktický test